###begin article-title 0
Amylase alpha-2A Autoantibodies
###end article-title 0
###begin p 1
###xml 36 57 36 57 <email xmlns:xlink="http://www.w3.org/1999/xlink">endot@yamanashi.ac.jp</email>
Corresponding author: Toyoshi Endo, endot@yamanashi.ac.jp
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE- The pathogenesis of autoimmune pancreatitis (AIP) and fulminant type 1 diabetes remains unclear, although it is known that immune-mediated processes severely compromise the endocrine and exocrine functions in both diseases.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
###xml 221 226 <span type="species:ncbi:9606">human</span>
###xml 395 400 <span type="species:ncbi:9606">human</span>
RESEARCH DESIGN AND METHODS- We have screened a lambdaTriplEx2 human pancreas cDNA library with serum from a patient with AIP and obtained positive clones. Sequence analysis revealed that 7 of 10 clones were identical to human amylase alpha-2A. Using a recombinant COOH-terminal amylase alpha-2A protein, we developed an enzyme-linked immunosorbent assay system to detect autoantibodies against human amylase alpha-2A.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
RESULTS- All 15 serum samples from patients with AIP recognized the recombinant protein, whereas sera from 25 patients with chronic alcoholic pancreatitis and sera from 25 patients with a pancreas tumor did not. Interestingly, 88% (15/17) of patients with fulminant type 1 diabetes were positive for an autoantibody against amylase alpha-2A. These antibodies were detected in 21% of patients with acute-onset type 1 diabetes (9 of 42) and 6% of type 2 diabetic patients (4 of 67).
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS- These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related.
###end p 6
###begin p 7
Published ahead of print at  on 10 November 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 32 35 32 35 <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" vol="58" page="520" id="N0x1c66890N0x3bdb120" xlink:href="19246601" ext-link-type="pubmed">520</related-article>
See accompanying commentary, p. 520.
###end p 9
###begin p 10
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 485 486 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 493 494 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
Recently, autoimmune pancreatitis (AIP), a unique form of chronic pancreatitis, has been reported as a discrete disease entity (1). It is characterized by 1) irregular narrowing of the main pancreatic duct and swelling of the pancreas, both of which are due to abundant lymphoplasmacytic inflammation to the exocrine pancreas (2); 2) the increased serum level of IgG and IgG4; 3) positive autoantibodies such as lactoferrin autoantibody or carbonic anhydrase II (CAII) autoantibody (3,4); and 4) a high prevalence of diabetes with complications (5).
###end p 10
###begin p 11
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
We recently reported that a high proportion of pancreatic islets and exocrine pancreatic tissues were infiltrated by CD4+ or CD8+ T-cells in the inflammatory process, which might induce diabetes in AIP (6). In addition, treatment with prednisolone improved insulin secretion and glycemic control in AIP patients (5). These data support the concept that autoimmune mechanism(s) plays a pivotal role in the destruction of the endocrine and exocrine pancreas in AIP patients with diabetes.
###end p 11
###begin p 12
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
Clinically, the most common initial symptom of AIP is jaundice, but in some patients, no symptoms or only mild symptoms, frequently without acute attacks of pancreatitis, may be present (7). It is difficult to distinguish AIP from other types of chronic pancreatitis or cancer of the pancreatic head (8). In such cases, detection of autoantibodies is useful for diagnosing AIP, but a proportion of patients with AIP are negative for autoantibodies against lactoferrin and CAII (3,4).
###end p 12
###begin p 13
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 22 29 <span type="species:ncbi:9606">patient</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
We encountered an AIP patient whose serum IgG and IgG4 levels were 3,498 and 2,430 mg/dl, respectively. It has been reported that median levels (5th and 95th percentiles) of IgG and IgG4 from patients with AIP were 2,389 mg/dl (1,349 and 4,310) and 742 mg/dl (265 and 1,150), respectively (3), so high concentrations of IgG in this case prompted us to search for new autoantigens associated with AIP. We also searched for the presence or absence of new autoantibodies in patients with abrupt onset and severe ketoacidosis-prone type 1 diabetes [called fulminant type 1 diabetes (9,10)], which involve the exocrine pancreas and the endocrine pancreas.
###end p 13
###begin title 14
RESEARCH DESIGN AND METHODS
###end title 14
###begin p 15
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
Serum used for screening the human pancreas cDNA library was obtained from a 67-year-old male patient (A.O.), who was admitted to our hospital complaining of slight abdominal pain and jaundice. Computed tomography revealed an enlarged pancreas, and laboratory findings showed high concentrations of IgG and IgG4. Tests for anti-lactoferrin and anti-CAII antibodies were both positive, but those for anti-nuclear antibody, anti-mitochondrial antibody, and rheumatoid factor were negative.
###end p 15
###begin p 16
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 955 957 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1045 1046 1041 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1100 1101 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1137 1138 1133 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1357 1359 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1360 1362 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1418 1420 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1488 1489 1459 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1497 1499 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1522 1523 1493 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1616 1623 1587 1594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 1675 1676 1646 1647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
###xml 1007 1015 <span type="species:ncbi:9606">patients</span>
###xml 1563 1571 <span type="species:ncbi:9606">patients</span>
###xml 1636 1644 <span type="species:ncbi:9606">patients</span>
Additional AIP sera were obtained from 14 newly diagnosed patients at the University of Yamanashi Hospital and Toranomon Hospital, Tokyo. Diagnosis of AIP was based on criteria proposed by the Japan Pancreas Society (11). Our 15 patients filled criterion 1 (narrowing of the main pancreatic duct or enlargement of pancreas by imaging studies), together with criterion 2 (high serum gamma-globulin, IgG, or IgG4 or the presence of autoantibodies, such as anti-nuclear antibodies and rheumatoid factor) and/or criterion 3 (marked interlobular fibrosis and prominent infiltration of lymphocytes and plasma cells in the periductal area). Serum samples were taken from 25 patients with chronic alcoholic pancreatitis, who were diagnosed according to a history of alcohol abuse, impaired exocrine pancreatic function, and the presence of calcified precipitates in the pancreas by imaging studies [Japan Pancreas Society, criteria for chronic pancreatitis 2001 (12)]. Twenty-five serum samples were recruited from patients with pancreas tumor (cancer [n = 8] and intraductal papillary mucinous tumor [IPMT, n = 17]). Fulminant type 1 diabetes (n = 17, 13 cases at the onset and 4 cases after onset) was diagnosed by criteria (fasting C-peptide </=0.033 nmol/l and A1C </=8.0% or summation operatorC-peptide </=0.540 nmol/l and A1C </=8.0%) as reported previously (13,14). Fulminant type 1 diabetes associated with pregnancy (15) was excluded from the present study. Acute-onset type 1 diabetes (n = 42) (12) and type 2 diabetes (n = 67) samples were also recruited. The patients' clinical characteristics are summarized in Table 1. Serum from patients with Hashimoto's thyroiditis (n = 47) were also studied. Diagnosis of the disease was made by elastic goiter and autoantibodies against both thyroglobulin and thyroid peroxidase. Control sera were obtained from 100 (59 male and 41 female) healthy volunteers.
###end p 16
###begin title 17
Immunoscreening.
###end title 17
###begin p 18
###xml 74 90 69 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 280 281 272 273 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 74 90 <span type="species:ncbi:562">Escherichia coli</span>
###xml 499 506 <span type="species:ncbi:9606">patient</span>
###xml 613 617 <span type="species:ncbi:9925">goat</span>
###xml 618 629 <span type="species:ncbi:3704">horseradish</span>
###xml 657 662 <span type="species:ncbi:9606">human</span>
The lambdaTriplEx2 human pancreas large insert cDNA library (HL5517u) and Escherichia coli XL-1 competent cells were obtained from BD Biosciences Clontech (Palo Alto, CA). The plaques on the plate were transferred to nitrocellulose filters presoaked with 10 mmol/l isopropyl-beta-d-thiogalactopyranoside (IPTG), washed with Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBST), and blocked with TBST containing 1% BSA. The filters were incubated overnight at 4degreesC with the sera from the patient with AIP (A.O.) at a dilution of 1:500. After washing four times with TBST, the filters then reacted with goat horseradish peroxidase-conjugated anti-human IgG (American Qualex, San Clemente, CA) at a dilution of 1:2,000 for 30 min at room temperature. The filters were also washed four times with TBST; positive reaction was detected with 3,3'-diaminobenzidine.
###end p 18
###begin title 19
###xml 31 36 <span type="species:ncbi:9606">human</span>
Preparation of the recombinant human AMY-2A.
###end title 19
###begin p 20
###xml 218 221 218 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 228 231 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 346 353 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 346 353 <span type="species:ncbi:562">E. coli</span>
A cDNA fragment of the positive clone was amplified by PCR with the sense primer, 5'-ATGGGGATCCTTGGGGTTTCGTACCTTCTGACAGA, and antisense primer, 5'-CTTCGAATTCCCAATTTAGATTCAGCATGAATTGC. The PCR product was digested with BamHI and EcoRI and then ligated into pTrc His B (Invitrogen, Carlsbad, CA). After sequencing, the plasmid was transfected into E. coli BL-21 (Novagen, Darmstadt, Germany). The production of the recombinant protein was inducted with 1 mmol/l IPTG and purified by His Bond column chromatography.
###end p 20
###begin title 21
Western blot analysis.
###end title 21
###begin p 22
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 536 551 530 545 <sc xmlns:xlink="http://www.w3.org/1999/xlink">immunoscreening</sc>
###xml 205 209 <span type="species:ncbi:9925">goat</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 377 381 <span type="species:ncbi:9925">goat</span>
###xml 382 393 <span type="species:ncbi:3704">horseradish</span>
###xml 421 426 <span type="species:ncbi:9606">human</span>
The 0.1% SDS-15% PAGE and transferring onto the nitrocellulose membrane was carried out as previously described (16) with slight modifications as follows: The membrane was blocked with 5% skim milk and 5% goat serum in TBS and then incubated with sera from the patients with AIP (1:500) overnight at 4degreesC. After washing five times with TBST, the membrane was reacted with goat horseradish peroxidase-conjugated anti-human IgG (1:2,000) for 30 min at room temperature. Positive reaction was detected by the same way as described in immunoscreening.
###end p 22
###begin title 23
In vitro translation and immunoprecipitation.
###end title 23
###begin p 24
###xml 208 209 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 302 304 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 437 439 437 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 314 319 <span type="species:ncbi:9606">human</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 497 502 <span type="species:ncbi:9606">human</span>
A cDNA fragment of AMY-2A was amplified by PCR with the sense primer, 5'-ATGGGGATCCATGTGGGGTTTCGTACCTTCTGACAGA, and antisense primer, 5'-CTTCGAATTCCCAATTTAGATTCAGCATGAATTGC, which added an ATG codon at the NH2-terminus. The PCR product was digested with BamHI and EcoRI and then ligated into pcDNA3.1. 35S-labeled human AMY-2A was prepared with PROTEIN script II (Ambion, Austin, TX) and [35S]methionine (GE Healthcare, Piscataway, NJ). 35S-AMY-2A was incubated with patients' sera (x100) or anti-human amylase antibody (x100; sc-12821; Santa Cruz Biotechnology, Santa Cruz, CA) in 200 mul PBS containing 1% BSA at 4degreesC overnight, with 10 mul GammaBind G Sepharose (GE Healthcare) added. After further incubation at room temperature for 60 min, the mixtures were centrifuged at 10,000 rpm for 5 min. The pellets were washed three times with PBS containing 0.05% Tween 20 (PBST). Final pellets were directly counted or dissolved with 10 mmol/l Tris-HCl (pH. 6.8) containing 0.1% SDS, boiled for 3 min, and loaded onto a 0.1% SDS-15% polyacrylamide gel.
###end p 24
###begin title 25
###xml 69 74 <span type="species:ncbi:9606">human</span>
Enzyme-linked immunosorbent assay for detecting autoantibody against human AMY-2A.
###end title 25
###begin p 26
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 798 799 787 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 801 802 790 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
###xml 528 532 <span type="species:ncbi:9925">goat</span>
###xml 533 544 <span type="species:ncbi:3704">horseradish</span>
###xml 572 577 <span type="species:ncbi:9606">human</span>
Autoantibody against human AMY-2A was measured by enzyme-linked immunosorbent assay (ELISA) using methods previously described (5). In brief, a microtiter plate (Coster 3590; Corning, Horseheads, NY) was coated with 50 mul 0.1 mug recombinant human AMY-2A overnight at 4degreesC. After washing the plate three times with PBST, the plate was incubated with 200 mul 1% BSA in PBS for 30 min. Next, the patients' sera were tested in triplicate at dilutions of 1:200 in 1% BSA for 1 h. The bound antibody was specially reacted with goat horseradish peroxidase-conjugated anti-human IgG (1:2,000) in 1% BSA for 30 min at room temperature. After washing, the plate was incubated with 100 mul 1-Step Slow TMB-ELISA (Pierce, Rockford, IL) for 30 min. The reaction was terminated by adding 100 mul 1 mol/l H2SO4, and absorbance was determined at an optical density of 450 nm. Intra- and interassay coefficient of variation, determined with the same lot of five ELISA plates, were 4.28 and 7.72%, respectively.
###end p 26
###begin title 27
Ethics.
###end title 27
###begin p 28
###xml 55 63 <span type="species:ncbi:9606">patients</span>
An ethical committee approved all study protocols, and patients gave informed consent.
###end p 28
###begin title 29
Statistical analysis.
###end title 29
###begin p 30
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical analysis was carried out using Fisher's exact test (JMP, Cary, NC), in which we considered statistically significant if P values were <0.05. Receiver operating characteristic (ROC) analysis was carried out with MedCalc (MedCalc Software, Mariakerke, Belgium).
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
###xml 22 27 <span type="species:ncbi:9606">human</span>
Cloning of cDNAs from human pancreas.
###end title 32
###begin p 33
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 515 521 515 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 52 59 <span type="species:ncbi:9606">patient</span>
###xml 230 235 <span type="species:ncbi:9606">human</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
We completely screened 2 x 104 plaques with the AIP patient's serum (A.O.) and obtained 10 positive clones. Nucleotide sequencing of the insert cDNAs and a subsequent homology search revealed that 7 of 10 clones were identical to human amylase-2A (AMY-2A). When compared with the nucleotide sequence of the human AMY-2A cloned by Wise et al. (17), four of seven clones contained the full coding sequence, whereas the 5' ends of the other three clones started from 61, 799, and 897 bp (A in ATG is designated as 1) (Fig. 1). Other nonamylase clones were those of the housekeeping genes, such as the heat shock protein and the nuclear protein.
###end p 33
###begin title 34
###xml 80 85 <span type="species:ncbi:9606">human</span>
Western blot analysis, immunoprecipitation, and ELISA system for detecting anti-human AMY-2A.
###end title 34
###begin p 35
###xml 250 256 250 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 355 362 355 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 413 414 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 407 414 407 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line 1</italic>
###xml 534 541 534 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lines 3</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 655 661 655 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line 2</italic>
###xml 25 32 <span type="species:ncbi:9606">patient</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 235 242 <span type="species:ncbi:9606">patient</span>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 355 367 <span type="species:ncbi:511693">E. coli BL21</span>
###xml 417 424 <span type="species:ncbi:9606">Patient</span>
###xml 559 566 <span type="species:ncbi:9606">patient</span>
Because IgG from the AIP patient used for screening recognized four different lengths of human AMY-2A clones, we hypothesized that the regions shared by these four clones, from codons 299 to 512, might contain a common epitope for the patient's IgG (Fig. 1). Therefore, we produced histidine-tagged human AMY-2A from codons 299 to 512 (AMY-2A/299-512) in E. coli BL21 and carried out Western blot analysis (Fig. 2A). Patient's serum (A.O.) recognized the 30-kDa recombinant protein (line 1), but sera from healthy volunteers did not (lines 3 and 4). When the patient's serum was preincubated with the recombinant protein, positive staining was abolished (line 2), suggesting that the autoantibody reacted with the recombinant protein, which contains the epitope.
###end p 35
###begin p 36
###xml 81 83 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 137 144 137 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 289 290 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 283 290 283 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 5 10 <span type="species:ncbi:9606">human</span>
###xml 39 43 <span type="species:ncbi:9925">goat</span>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
Anti-human AMY-2A antibody produced in goat was bound to the in vitro-translated 35S-AMY-2A and was precipitated by protein G-sepharose (Fig. 2B). IgG from two patients with AIP also bound to the labeled protein and was precipitated, but the IgG from two healthy volunteers did not (Fig. 2B). This recombinant fluid phase autoantibody assay with in vitro transcription and translation of AMY-2A without additional amino acids, such as His-Tag, confirmed the specificity of the autoantibody against the protein.
###end p 36
###begin p 37
###xml 250 252 250 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 291 292 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 285 292 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 397 404 397 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 512 519 512 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 682 683 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 676 683 676 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>F</italic></xref>
###xml 686 693 686 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 831 832 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 163 170 <span type="species:ncbi:9606">patient</span>
###xml 420 427 <span type="species:ncbi:9606">patient</span>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
Next, by coating the protein onto the plate, we developed an ELISA system for detecting anti-amylase antibodies in the serum. When compared with the normal serum, patient sera showed strong signals, which were well correlated with immunoprecipitated 35S-AMY-2A by protein G-sepharose (Fig. 2C). This positive reaction in ELISA was displaced in a concentration-dependent fashion by AMY-2A/299-512 (Fig. 2D). When the AIP patient's serum (A.O.) was diluted, we could detect positive signals up to x1,000 dilution (Fig. 2E). To obtain a cutoff value for positivity, we carried out ROC analysis of the healthy volunteers (n = 100) and fulminant type 1 diabetic patients (n = 17) (Fig. 2F). Table 2 shows criterion values and coordinates of the ROC curve. When the value was set as 34 (area under the ROC curve 0.92; significance level P = 0.0001), sensitivity, specificity, and positive predictive value were 88.24, 99.0, and 93.7%, respectively.
###end p 37
###begin title 38
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Prevalence of autoantibody against human AMY-2A in AIP patients.
###end title 38
###begin p 39
###xml 139 145 139 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 292 293 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 444 445 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 457 458 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 634 635 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 628 635 628 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
Using the ELISA system, we determined the prevalence of autoantibody against human AMY-2A in AIP patients and various pancreatic diseases (Fig. 3). All 15 IgGs from patients with AIP were positive for AMY-2A/299-512, whereas 1 of 100 IgGs from control subjects was positive for the antibody (P < 0.001, Fisher's exact test). All the IgGs from the patients with chronic alcoholic pancreatitis (n = 25) or with pancreas tumor (pancreatic cancer, n = 8; IPMT, n = 17) were negative for the antigen. Antibodies were detected in 9% (4/47) of patients with Hashimoto's thyroiditis, a representative organ-specific autoimmune disease (Fig. 3A).
###end p 39
###begin p 40
###xml 8 9 8 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 0 9 0 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Figure 3<italic>B</italic></xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 124 131 <span type="species:ncbi:9606">patient</span>
###xml 551 558 <span type="species:ncbi:9606">patient</span>
Figure 3B shows the time course of the autoantibody titer from two AIP patients before and after prednisolone treatment. In patient A.O., IgG4 gradually increased and reached 5,540 mg/dl, but administration of prednisolone initiated a rapid decrease of IgG4 to 571 mg/dl. Before prednisolone treatment, the titer of the autoantibody against AMY remained high, and prednisolone treatment induced a rapid decrease of the titer of AMY-2A autoantibody to a normal level. The fall rate of the antibody titer seemed to be parallel to that of serum IgG4. In patient T.M., administration of prednisolone also rapidly decreased the titer of the autoantibody against AMY. The autoantibodies did not increase even at the drug maintenance dose in both cases.
###end p 40
###begin title 41
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Prevalence of autoantibody against human AMY-2A in patients with fulminant type 1 diabetes and acute-onset type 1 diabetes.
###end title 41
###begin p 42
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 208 214 208 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
We next studied the prevalence of autoantibody against human AMY-2A in various types of diabetic patients (fulminant type 1 diabetes, n = 17; acute-onset type 1 diabetes, n = 42; and type 2 diabetes, n = 67; Fig. 4). Interestingly, 88% of patients with fulminant type 1 diabetes were positive for the autoantibody, but 1% of control was positive for the antibody (P < 0.001, Fisher's exact test). The autoantibody was detected with low frequency in patients with acute-onset type 1 diabetes (21%, 9 of 42) and patients with type 2 diabetes (6%, 4 of 67).
###end p 42
###begin title 43
DISCUSSION
###end title 43
###begin p 44
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 62 66 <span type="species:ncbi:9606">girl</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
In 2002, Barera et al. (18) reported a case of an 11-year-old girl with celiac disease and hypothyroidism. Because of hyperamylasemia, she was suspected to have chronic pancreatitis, but no pancreatic damage was demonstrated. By using ELISA to detect autoantibodies to amylase, they found that she produced an autoantibody against porcine amylase and that this declined after the institution of a gluten-free diet. In the present study, we also detected an autoantibody against pancreas-specific AMY-2A in all of the AIP patients, but not in patients with chronic alcoholic pancreatitis and with pancreatic tumors.
###end p 44
###begin p 45
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 346 347 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 348 349 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 350 352 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
The presence of autoantibodies against CAII, lactoferrin, and pancreatic secretory trypsin inhibitor (PSTI) has been reported (3,4,19). However, the distribution of these molecules is non-organ specific (20-22), and the prevalence of these autoantibodies against CAII, lactoferrin, and PSTI in AIP is rather low, ranging from 42approximately73% (3,4,19). Using 13 serum samples from our AIP patients, we carried out ELISA assays for autoantibodies against CAII and lactoferrin. As a result, 66% (10 of 15) were positive for CAII, and 53% (8 of 15) were positive for lactoferrin. Thus, an autoantibody against AMY-2A might be a more sensitive marker for AIP than that of CAII, lactoferrin, or PSTI.
###end p 45
###begin p 46
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 71 75 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 314 319 <span type="species:ncbi:9606">human</span>
Furthermore, the adoptive transfer of amylase-specific CD4+ T-cells to rats was able to confer pancreatitis, whereas the transfer experiment with lactoferrin-specific or CAII-specific CD4+ T-cells failed to induce experimental pancreatitis (23). Our findings of a high prevalence of autoantibody against AMY-2A in human AIP and the results from the adoptive transfer experiment of amylase-specific CD4+ T-cells to rodents suggest that cellular and/or humoral autoimmunity against AMY-2A plays some role in the pathogenesis of AIP.
###end p 46
###begin p 47
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 354 360 354 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
Approximately 80% of patients with chronic pancreatitis are alcoholic, the pathogenesis of which still remains unclear. However, it is well known that acute or chronic alcohol exposure suppresses all branches of the immune system (24), and none of our sera from patients with chronic alcoholic pancreatitis were positive for autoantibody against AMY-2A (Fig. 3). Therefore, an assay for autoantibody against AMY-2A is useful for distinguishing AIP from chronic alcoholic pancreatitis.
###end p 47
###begin p 48
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 442 444 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 511 512 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 550 551 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 605 606 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 642 643 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 732 733 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 795 796 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 839 841 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1128 1130 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1172 1173 1159 1160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1181 1182 1168 1169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1335 1337 1322 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
It is of particular interest that anti-AMY-2A autoantibody is detected in 88% of patients with fulminant type 1 diabetes. Fulminant type 1 diabetes is a recently proposed subtype of type 1B, nonimmune-mediated, or idiopathic type 1 diabetes (9,10). A nationwide survey revealed that fulminant diabetes accounted for approximately20% of Japanese type 1 diabetes with ketosis or ketoacidosis and flu-like symptoms frequently observed at onset (25). Clinical characteristics of this subtype of type 1 diabetes are 1) remarkably abrupt onset of disease; 2) very short (<1 week) duration of diabetic symptoms; 3) severe ketoacidosis at diagnosis; 4) negative status of islet-related autoantibodies, such as GADAb and anti-IA-2 antibody; 5) virtually no C-peptide secretion (10 mug/day in urine); and 6) elevated serum pancreatic enzyme levels (26). These features and the absence of insulitis in patients' pancreases have led some to hypothesize that an autoimmune mechanism does not contribute to the development of fulminant type 1 diabetes, but rather that viral infection plays a central role in the pathogenesis of the disease (27). However, we previously demonstrated CD4+ and CD8+ T-cell infiltration to pancreatic exocrine cells and to the islet in an autopsy case deceased immediately after the onset of fulminant type 1 diabetes (28).
###end p 48
###begin p 49
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 186 193 <span type="species:ncbi:9606">patient</span>
Imagawa and Hanafusa (27) also confirmed cellular infiltration of pancreatic islets in patients with fulminant type 1 diabetes. Shimada et al. (29) described a fulminant type 1 diabetic patient with a high serum level of CXCL10, a chemokine that induces migration of activated T-cells to local lesions and GAD-reactive CD4+ cells in the periphery. These results, and the presence of an autoantibody against AMY-2A, suggest that the disease might be autoimmune-related, involving the exocrine and the endocrine pancreas (10,28).
###end p 49
###begin p 50
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
Exocrine dysfunction and impaired glucose tolerance are common features for both AIP and fulminant type 1 diabetes. With regard to the HLA genotype, Kawa et al. (30) demonstrated that the DRB1*0405-DQB1*0401 haplotype is closely associated with AIP in the Japanese population, and Tanaka et al. (31) revealed that the DQA1*0303-DQB1*0401 haplotype is strongly associated with fulminant type 1 diabetes in a homologous manner. When we studied the frequency of this allele in our patients with AIP, 5 of 15 patients were heterozygous for the DRB1*0405-DQB1*0401 haplotype. Although further study with larger sample sizes will be needed, these two reports and our own analysis suggest the importance of the DQB1*0401 allele in both diseases. Furthermore, we are able to detect autoantibody against AMY-2A in both with nearly the same prevalence. Although further investigation is needed, the present results suggest that clinically and immunologically, AIP and fulminant type 1 diabetes are closely related to one another.
###end p 50
###begin p 51
No potential conflicts of interest relevant to this article were reported.
###end p 51
###begin p 52
We acknowledge T. Hugh for his editorial work.
###end p 52
###begin title 53
REFERENCES
###end title 53
###begin p 54
###xml 280 282 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 224 229 <span type="species:ncbi:9606">human</span>
Cloning of human amylase alpha-2A cDNAs from lambdaTriplEx2 human pancreas cDNA library. Seven clones of human amylase alpha-2A cDNAs. Their lengths and 5'-ends are shown (A in ATG is designated as 1). The top bar indicates human amylase alpha-2A cDNA as reported by Wise et al. (17), and the common regions shared by all seven clones, from codons 299 to 512, are shown in the bottom bar.
###end p 54
###begin p 55
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 322 328 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line 1</italic>
###xml 355 362 355 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lines 3</italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 472 473 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 498 500 497 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 526 528 525 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 575 581 574 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line 1</italic>
###xml 601 607 600 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line 2</italic>
###xml 634 641 633 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lines 3</italic>
###xml 646 647 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 684 691 683 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lines 5</italic>
###xml 696 697 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 869 870 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1205 1206 1204 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1521 1522 1514 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1702 1703 1695 1696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1839 1840 1832 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1888 1889 1881 1882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 313 320 <span type="species:ncbi:9606">patient</span>
###xml 383 390 <span type="species:ncbi:9606">patient</span>
###xml 556 560 <span type="species:ncbi:9925">goat</span>
###xml 591 595 <span type="species:ncbi:9925">goat</span>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
###xml 972 977 <span type="species:ncbi:9606">human</span>
###xml 1042 1047 <span type="species:ncbi:9606">human</span>
###xml 1069 1077 <span type="species:ncbi:9606">patients</span>
###xml 1289 1296 <span type="species:ncbi:9606">patient</span>
###xml 1586 1593 <span type="species:ncbi:9606">patient</span>
###xml 1774 1782 <span type="species:ncbi:9606">patients</span>
###xml 1878 1886 <span type="species:ncbi:9606">patients</span>
Western blot analysis and ELISA for detecting anti-human AMY-2A. A: Western blot analysis. Recombinant human AMY-2A (50 ng) from codons 299 to 512 (AMY-2A/299-512) was electrophoresed in 0.1% SDS-15% polyacrylamide and transferred onto a nitrocellulose filter. The filters reacted with serum (x1,000) from an AIP patient (line 1) and normal control sera (lines 3 and 4). Line 2, AIP patient's serum preincubated with 1 mug/ml AMY-2A/299-512. MW, molecular weight markers. B: Immunoprecipitation of 35S-AMY-2A with antibodies. 35S-AMY-2A was incubated with goat anti-amylase (line 1), normal goat IgG (line 2), sera from AIP patients (lines 3 and 4), and sera from healthy volunteers (lines 5 and 6) and then precipitated with protein G-sepharose. The pellets were electrophoresed in 0.1% SDS-15% polyacrylamide and analyzed with Bas 2000 image analyzer (Fujix, Tokyo). C: Correlation between the result of ELISA and that of immunoprecipitation. By coating the recombinant human AMY-2A/299-512, we developed an ELISA system for detecting anti-human AMY-2A. Sera from 11 patients with AIP (*) and two normal control subjects (o) were assayed by ELISA and immunoprecipitation for detecting the autoantibody. D: Absorption of positive ELISA signal with recombinant AMY-2A. One milliliter of a patient's serum (1:500) was preincubated with the recombinant protein at the indicated dose overnight at 4degreesC, and then the serum was used as the first antibody. The data are the mean of triplicate values. OD, optical density. E: Serum dilution experiment in ELISA assay. Positive serum from patient A.O. was diluted as indicated, and ELISA assay was carried out. The data are the mean of triplicate values. F: ROC analysis of the healthy volunteers and fulminant type 1 diabetic patients. We carried out ROC analysis of the healthy volunteers (n = 100) and fulminant type 1 diabetic patients (n = 17) with MedCalc.
###end p 55
###begin p 56
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 386 413 386 413 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 763 768 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1012 1017 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
###xml 643 650 <span type="species:ncbi:9606">patient</span>
###xml 703 708 <span type="species:ncbi:9606">human</span>
###xml 874 881 <span type="species:ncbi:9606">patient</span>
Prevalence of autoantibody against human AMY-2A in patients with various pancreatic diseases. A: Prevalence of autoantibody against human AMY-2A in patients with AIP (n = 15), chronic alcoholic pancreatitis (CP, n = 25), pancreatic tumor (PT, n = 25), control subjects from healthy volunteers (C, n = 100), and Hashimoto's thyroiditis (H, n = 47) was examined by ELISA, as described in research design and methods. The data are the mean of triplicate values. The dotted line shows a cutoff value. Fisher's exact test was carried out between AIP and control groups. *P < 0.001. B: Time course of anti-AMY antibody and IgG4 of AIP patients. AIP patient (A.O.), whose IgG was used to screen lambdaTriplEx2 human pancreas cDNA library, was treated with prednisolone (arrow). Before and after the treatment, anti-AMY antibody (*-*) and IgG4 (o-o) were measured. In the other AIP patient (T.M.), titer of the anti-AMY antibody (black triangle-black triangle) was also measured before and after prednisolone treatment (arrow).
###end p 56
###begin p 57
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 377 404 377 404 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 579 580 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 127 132 <span type="species:ncbi:9606">human</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
Prevalence of autoantibody against human AMY-2A in patients with various types of diabetes. Prevalence of autoantibody against human AMY-2A (*) in patients with fulminant type 1 diabetes (FT1DM, n = 17), acute-onset type 1 diabetes (AT1DM, n = 42), type 2 diabetes (T2DM, n = 67), and control subjects from healthy volunteers (C, n = 100) was studied by ELISA, as described in research design and methods. The data are the mean of triplicate values. The dotted line shows a cutoff value. Fisher's exact test was carried out between fulminant type 1 diabetic and control groups. *P < 0.001.
###end p 57
###begin p 58
Clinical characteristics of subjects
###end p 58
###begin p 59
Data are medians (95% CI) or means +/- SD. PSL, prednisolone; IPMT, intraductal papillary mucinous tumor.
###end p 59
###begin p 60
Duration from the onset of diabetes to the time of sample collection.
###end p 60
###begin p 61
At onset; within 3 months after onset.
###end p 61
###begin p 62
Criterion values and coordinates of the ROC curve
###end p 62
###begin p 63
Data in parentheses are 95% CI.
###end p 63
###begin p 64
Cutoff value for positivity.
###end p 64

